Tofacitinib could be a treatment approach for the management of psoriasis and psoriatic arthritis

Primary tabs

Tofacitinib could be a treatment approach for the management of psoriasis and psoriatic arthritis

The Tofacitinib, a JAK inhibitor presents the excellent potential for psoriasis and psoriatic arthritis treatment, as per recent research carried out by the scientists of Chapel Allerton Hospital and Bradford Teaching Hospitals. These are the immune-mediated health issues leading to significant functional disability and reduced quality of life. Further, due to clinical heterogeneity associated with these problems, the management becomes difficult.

The currently used approaches for managing psoriatic arthritis (PsA) involves TNF inhibitors, but due to related side effects and inadequate response among some of the patients, safer treatment options are needed. Other options include oral JAKs (Janus kinase) inhibitors which inhibit psoriatic inflammation modulation at articular and extraarticular positions.

The study involved the analysis of recently published studies concerning JAK inhibitors role in PsA. The PubMed, Google Scholar and were searched for relevant literature. OPAL Broaden and OPAL Beyond phase III studies were used to demonstrate Tofacitinib efficacy with approval from EMA and FDA. The study exhibited positive outcomes of Tofacitinib for moderate to severe plaque psoriasis in OPT Retreatment studies and OPT Pivotal 1 and 2. However, the FDA approval was refused for this implication due to long-term safety concerns. Additional analysis is required to evaluate Tofacitinib related safety concerns.


Expert Review of Clinical Immunology

Link to the source:

Original title of article:

Tofacitinib for the treatment of psoriasis and psoriatic arthritis


Anna Berekmeri et al.

Therapeutic, Tofacitinib, Psoriatic Arthritis, Joints, Skin, JAK Inhibitors, Efficacy, Safety
Log in or register to post comments